Design Therapeutics reports Q2 net loss $15M; holds $359.4M cash; initial FA data expected Q4 2022

Design Therapeutics, Inc.

2022-Q2 EPS reported -$0.51

Net loss of $15.0M for Q2 2022; R&D expenses $11.3M; G&A expenses $4.3M.
Cash, equivalents and securities totaled $359.4M as of June 30, 2022, providing multi-year runway.
Initial Phase 1 single-ascending dose data for DT-216 in Friedreich ataxia expected Q4 2022.
Clinical development for myotonic dystrophy type-1 GeneTAC program anticipated in 2023.
Preclinical FECD program advancing; molecules showed nearly complete reduction in toxic RNA foci in vitro.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.